Page last updated: 2024-12-05

aziridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9033
CHEMBL ID540990
CHEBI ID30969
MeSH IDM0102949

Synonyms (105)

Synonym
aziridin
nsc-124034
montrek 6
wln: /t3mtj/
nsc124034
nsc-134422
nsc134422
nsc124036
ethylenimine resins
tydex 12
epomine 150t
everamine
nsc-124036
epomine p 1000
pei 12
dow pei-600e
nsc124035
pei 100
dow pei-18
pei 1000
epamine 150t
montrek 1000
pei 1120
montrek pei 18
PEI ,
epomine 1000
pei 400
pei 1
pei 2
pei 6
everamine 210t
pei 600
pei 18
p 1000
montrek pei 6
nsc-124035
dow pei-6
pei-600
9002-98-6
everamine 50t
ethyleneimine
ei
dimethyleneimine
CHEBI:30969 ,
azacyclopropane
ethylenimine
aziridin [german]
dihydroazirene
brn 0102380
tl 337
ai3-50324
aethylenimin [german]
hsdb 540
dihydro-1h-azirine
1h-azirine, dihydro-
etilenimina [italian]
rcra waste no. p054
dihydroazirine
aziran
un1185
ethyleenimine [dutch]
ent-50324
ccris 296
ethylene imine
einecs 205-793-9
rcra waste number p054
49553-93-7
inchi=1/c2h5n/c1-2-3-1/h3h,1-2h
aziridine ,
151-56-4
nsc-196335
nsc196335
CHEMBL540990
AKOS005366671
unii-54p5fex9fh
5-20-01-00003 (beilstein handbook reference)
etilenimina
54p5fex9fh ,
ethyleneimine, inhibited [un1185] [poison]
ethyleenimine
aethylenimin
ethyleneimine, inhibited
ec 205-793-9
STL168030
68130-99-4
FT-0688199
68130-98-3
aziridine [iarc]
aziridine [inci]
ethylenimine [mi]
ethyleneimine [hsdb]
un 1185 (salt/mix)
STR07159
polyethyleneimine, branched
FT-0699349
DTXSID8020599 ,
aziridine (ethyleneimine), stabilized with 1-2% naoh
mfcd00039669
CS-0058423
Q409141
BCP29842
ethyleneimine;aziridine;ethylenimine
aziridine;ethylenimine
aziridine 100 microg/ml in methanol
polyethylenimine linear

Research Excerpts

Actions

ExcerptReferenceRelevance
"Aziridines inactivate viruses in a first-order reaction and the inactivation rate and endpoint can be determined."( Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine.
Bahnemann, HG, 1990
)
1

Toxicity

ExcerptReferenceRelevance
" The cytotoxicity assay indicated that they all are less toxic than PEI 25000."( Polyaspartamide-based oligo-ethylenimine brushes with high buffer capacity and low cytotoxicity for highly efficient gene delivery.
Huang, SW; Liu, M; Xue, YN; Zhang, M; Zhuo, RX, 2009
)
0.35

Compound-Compound Interactions

The potential application of administering irofulven in combination with aziridine-containing chemotherapeutic agents was evaluated in this study. Human lung carcinoma MV522 cells and BALB/c athymic mice were used.

ExcerptReferenceRelevance
" The potential application of administering irofulven in combination with aziridine-containing chemotherapeutic agents was evaluated in this study."( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002
)
0.55
"Human lung carcinoma MV522 cells and BALB/c athymic mice bearing the human lung carcinoma MV522 xenograft were used to evaluate the activity of irofulven in combination with aziridine-containing drugs."( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002
)
0.51
"Irofulven in combination with either thiotepa or mitomycin C demonstrated a strong synergistic (supraadditive) activity both in vitro and in vivo, that exceeded results obtained with monotherapy at the same or higher doses of these agents."( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002
)
0.31
"These results indicate that the therapeutic activity of irofulven is enhanced when combined with mitomycin C or thiotepa, and further evaluation of these combinations is therefore warranted."( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002
)
0.31

Bioavailability

ExcerptReferenceRelevance
"In principle, not only efficient but rapid transfection is required since it can maximize the bioavailability of vector-carried gene prior to the cellular excretion."( Acidity-responsive gene delivery for "superfast" nuclear translocation and transfection with high efficiency.
Feng, J; Jia, HZ; Qin, SY; Wan, SS; Zeng, X; Zhang, XZ; Zhu, JY; Zhuo, RX, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
saturated organic heteromonocyclic parent
aziridines
azacycloalkane
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID432746Dissociation constant of the compound2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Aziridine alkaloids as potential therapeutic agents.
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (390)

TimeframeStudies, This Drug (%)All Drugs %
pre-199074 (18.97)18.7374
1990's43 (11.03)18.2507
2000's97 (24.87)29.6817
2010's158 (40.51)24.3611
2020's18 (4.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.64 (24.57)
Research Supply Index6.00 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index88.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.25%)5.53%
Reviews18 (4.47%)6.00%
Case Studies8 (1.99%)4.05%
Observational0 (0.00%)0.25%
Other376 (93.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]